期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

培哚普利联合厄贝沙坦调节扩张型心肌病大鼠AT_1受体和lamin A表达

Combination Therapy with Perindopril and Irbesartan Regulates the Expression of AT_1 Receptor and Lamin A in a Rat Model of Dilated Cardiomyopathy
下载PDF
导出
摘要 目的:探讨培哚普利联合厄贝沙坦对扩张型心肌病(DCM)大鼠心肌血管紧张素Ⅱ1型受体(AT_1 Rs)和核纤层蛋白A (lamin A)mRNA表达的调节。方法:腹腔注射阿霉素建立SD大鼠DCM模型。13周后大鼠分为4组:A组为正常大鼠,B组为DCM大鼠,均不予药物干预;C、D组均为DCM大鼠,C组予以培哚普利,D组予以培哚普利联合厄贝沙坦。超声心动图检测大鼠左室射血分数(LVEF);RT—PCR方法检测AT_1Rs、lamin A表达。结果:(1)C、D组干预后LVEF明显升高(P＜0．01),D组LVEF高于C组(P＜0．05)。(2)与A组比较,B组AT_1Rs表达下调(P＜0．05);与B组比较,C、D组AT_1 Rs表达上调(P＜0．05),D组AT_1Rs表达上调更明显。(3)与A组比较,B组lamin A表达下调(P＜0．05);D组lamin A表达水平高于B组(P＜0．05)。结论:DCM的发展伴随心肌AT_1Rs及lamin A表达下调。培哚普利联合厄贝沙坦使AT_1Rs表达明显上调及lamin A表达上调,有利于DCM心力衰竭的治疗。 Objective：To determine the mRNA expression of Angiotensin Ⅱ type 1 receptors （ AT1Rs ） and lamin A regulated by combination therapy with perindopril and irbesartan in the myocardium of a rat model of dilated cardiomyopathy （ DCM ）. Methods：Sprague-Dawley rats were administered adriamyein intraperitoneally to develop DCM. 13 weeks later, the survivors were divided into 4 groups, group A contained normal rats, and group B contained rats with DCM. Both these groups were not given drug treatment. Group C and groups D contained rats with DCM, however, group C was administered perindopril and group D was administered perindopril and irbesartan. Left ventricular ejection fraction （ LVEF ） was measured by echocardiogram and the expression of＂ AT1Rs and lamin A was detected by RT-PCR. Results： （1） LVEF in both goup C and group D as much higher after intervention compared with that before intervention （ P〈0.01 ）, and group D LVEF was higher than that of group C （P〈0.05）. （ 2 ） Compared with group A, group B expression levels of AT1Rs were down-regulated （P〈0.05）. Compared with B group B, both group C and group D expression levels of AT1Rs were upregulated （ P〈0. 05 ）, and group D expression levels of AT1Rs were more obviously upregulated. （ 3 ） Compared with group A, group B expression levels of lamin A were down-regulated （ P〈0.05 ）. Group D expression levels of lamin A were higher than those of group B（ P〈0.05 ）. Conclusion：The development of DCM is hccompanied by down regulation of the expression of AT1Rs and lamin A. Combination therapy with perindopril and irbesartan can obviously up-regulate the expression of AT1Rs and up-regulate the expression of lamin A, which may contribute to the better therapeutic effects in the heart failure of DCM.
作者 马国添 谢秀梅 陈晓彬 申定珠 方叶青
机构地区 中南大学湘雅医院心内科 广西医科大学第一附属医院老年心内科 中南大学湘雅医院中西医结合研究所
出处 《中国临床医学》 北大核心 2007年第1期46-49,共4页 Chinese Journal of Clinical Medicine
基金 湖南省教育厅"十五"重点学科建设项目[湘教发(2005)100]
关键词 血管紧张素转换酶抑制剂 血管紧张素Ⅱ 1型受体阻滞剂 扩张型心肌病 血管紧张素1型受体 A型核纤 层蛋白 Angiotensin-converting enzyme inhibitors Angiotensin Ⅱ Type 1 receptor blockers Dilated cardiomyopathy Angiotensin Type 1 receptor Lamin Type A
分类号 R542.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献15

  • 1Ghanem FA,Movahed A.Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?[J].Rev Cardiovasc Med,2005,6(4):206-213.
  • 2Sebillon P,Bouchier C,Bidot LD,et al.Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations[J].J Med Genet,2003,40(8):560-567.
  • 3Nikolova V,Leimena C,McMahon AC,et al.Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice[J].J Clin Invest,2004,113(3):349-351.
  • 4Schwarz ER,Pollick C,Dow J,et al.A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography[J].Cardiovasc Res,1998,39(1):216-223.
  • 5Teraoka K,Hirano M,Yamaguchi K,et al.Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats[J].Eur J Heart Fail,2000,2(4):373-378.
  • 6Watanabe K,Saito Y,Ma M,et al.Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy[J].J Cardiovasc Pharmacol,2003,42,Suppl 1:105-109.
  • 7Berthonneche C,Sulpice T,Tanguy S,et al.AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats[J].Cardiovasc Drugs Ther,2005,19(4):251-259.
  • 8Ishiyama Y,Gallagher PE,Averill DB,et al.Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin Ⅱ receptors[J].Hypertension,2004,43(5):970-976.
  • 9Becari C,Sivieri DO Jr,Santos CF,et al.Role of elastase-2 as an angiotensin Ⅱ-forming enzyme in rat carotid artery[J].J Cardiovasc Pharmacol,2005,46(4):498-504.
  • 10Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention[J].Circulation,2006,113(14):1807-1816.

二级参考文献12

  • 1Serneri GG, Boddi M, Cecioni I, et al. Cardiac angiotensin Ⅱformation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res, 2001, 88(9): 961-968.
  • 2Schultz, JE, Witt SA, Glascock BJ, et al. TGF- β mediates the hypertrophic cardiomyocyte growth induced by angiotensin Ⅱ. J Clin Invest, 2002, 109 (6): 787-796.
  • 3Lorell BH. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease. Am J Cardiol, 1999, 83(12A): 48-52.
  • 4Akishita M, Yamada H, Dzau VJ, et al. Increased vasoconstrictor response of the mouse lacking angiotensin Ⅱ type 2 receptor.Biochem Biophys Res Commun, 1999, 261(2): 345-349.
  • 5Brogelli L, Parenti A, Ledda F. Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in vitro organ culture model. J Cardiovasc Pharmacol, 2002, 39(5) :739-745.
  • 6Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trail against atenold. Lancet, 2002, 359(9311): 995～1003.
  • 7Dickstein K. ELITE Ⅱ and Val- HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med,2001, 2 (5): 240-243.
  • 8Pitt B, Poole- Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- - the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet, 2000, 355 (9215) :1582～1587.
  • 9Lee S, Kramer CM, Mankad S, et al. Combined angiotensin converting enzyme inhibition and angiotensin AT1 receptor blockade up- regulates myocardial AT2 receptors in remodeled myocardium post - infarction. Cardiovasc Res, 2001, 51(1):131～139.
  • 10杜乃立,戚文航,朱鼎良,高平进,邱喜盛.血管紧张素Ⅱ及其受体拮抗剂对心肌细胞肥大的影响[J].高血压杂志,2001,9(2):130-133. 被引量：5

共引文献9

中国临床医学
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部